S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Dyadic International , Inc. (NASDAQ:DYAI) reported the results of its 2025 annual meeting of shareholders held Friday, according to a press release statement based on the company’s filing with the Securities and Exchange Commission.
Shareholders elected Mark A. Emalfarb as a Class III director to serve until the company’s 2028 annual meeting. The vote count for Emalfarb was 15,946,385 shares in favor and 421,896 shares withheld, with 7,892,709 broker non-votes.
Shareholders also ratified the appointment of Crowe LLP as Dyadic’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The firm received 24,013,307 votes in favor, 237,523 votes against, and 10,160 abstentions.
An advisory vote on the compensation of the company’s named executive officers received 15,765,072 votes in favor, 522,744 votes against, and 80,465 abstentions, with 7,892,709 broker non-votes.
On the advisory vote regarding the frequency of future votes on executive compensation, 15,443,558 shares were voted for a one-year interval, 716,692 for two years, 13,576 for three years, and 194,455 abstained. Based on these results, the board of directors and the Compensation Committee determined that future advisory votes on executive compensation will occur annually.
The information in this article is based solely on a press release statement and the company’s SEC filing.
In other recent news, Dyadic International reported its first-quarter 2025 financial results, revealing a net loss of $0.07 per share, which met analyst expectations. Revenue for the quarter was $393,570, slightly below the forecast of $394,000, but an increase from $335,000 in the same quarter last year. This growth was primarily attributed to grant revenue from the Gates Foundation and CEPI. Dyadic is focusing on commercializing non-pharmaceutical products, including recombinant human serum albumin, expected to launch in the third quarter of 2025. The company has also reduced its number of paid collaborators from nine to four, signaling a strategic shift toward product-driven revenue generation. Additionally, Dyadic appointed Joe Hazelton as its new President to drive growth and strategic initiatives. The company has recently validated its commercial strategy through partnerships with Proliant Health and Biologicals and a joint venture with Fermbox Bio. These developments indicate Dyadic’s ongoing transition from a development-stage biotech firm to a product-driven enterprise.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.